Develops anti-infective therapies for immunocompromised patients, focusing on severe infectious diseases. Founded as a Bayer spin-off, the company's lead antiviral pritelivir won FDA approval in October 2026 following its acquisition by Asahi Kasei.
The FDA approved Asahi Kasei's pritelivir, to be sold as Hovilpri, for HSV-caused mucocutaneous lesions in immunocompromised adults refractory to standard nucleoside analogues — the first new mechanism for HSV treatment in nearly three decades.